Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
EXAS

EXAS - Exact Sciences Corp Stock Price, Fair Value and News

47.56USD-1.81 (-3.67%)Market Closed

Market Summary

EXAS
USD47.56-1.81
Market Closed
-3.67%

EXAS Stock Price

View Fullscreen

EXAS RSI Chart

EXAS Valuation

Market Cap

8.8B

Price/Earnings (Trailing)

-36.53

Price/Sales (Trailing)

3.46

EV/EBITDA

-72.63

Price/Free Cashflow

-429.03

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

73.67%

EBT Margin

-9.38%

Return on Equity

-7.67%

Return on Assets

-3.77%

Free Cashflow Yield

-0.23%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

5.82%

Rev. Growth (Qtr)

-1.45%

EXAS Earnings

Earnings (TTM)

-240.2M

Earnings Growth (Yr)

-48.65%

Earnings Growth (Qtr)

-121.49%

Breaking Down EXAS Revenue

Last 7 days

6.1%

Last 30 days

13.5%

Last 90 days

-21.9%

Trailing 12 Months

-51.7%

How does EXAS drawdown profile look like?

EXAS Financial Health

Current Ratio

1.64

Debt/Equity

0.5

Debt/Cashflow

0.07

EXAS Investor Care

Shares Dilution (1Y)

2.30%

Diluted EPS (TTM)

-1.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.5B000
20232.2B2.3B2.4B2.5B
20221.9B1.9B2.0B2.1B
20211.5B1.7B1.8B1.8B
20201.1B1.1B1.3B1.5B
2019526.2M623.2M723.7M876.3M
2018307.9M353.2M398.9M454.5M
2017132.9M169.4M213.8M266.0M
201650.0M63.1M78.6M99.4M
20155.8M13.9M26.5M39.4M
20143.4M2.4M1.3M1.8M
20134.1M4.1M4.1M4.1M
20124.2M4.2M4.2M4.1M
20115.1M4.8M4.5M4.2M
201005.0M5.1M5.3M
20090004.8M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exact Sciences Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 13, 2024
levangie daniel j
acquired
-
-
5,444
-
Jun 13, 2024
barber michael j
acquired
-
-
5,444
-
Jun 13, 2024
clancy paul j
acquired
-
-
5,444
-
Jun 13, 2024
coward d scott
acquired
-
-
5,444
-
Jun 13, 2024
petrovic shacey
acquired
-
-
5,444
-
Jun 13, 2024
sebelius kathleen
acquired
-
-
6,889
-
Jun 13, 2024
zanotti katherine s
acquired
-
-
5,444
-
Jun 13, 2024
doyle james edward
acquired
-
-
5,444
-
May 01, 2024
coward d scott
sold
-4,030
60.15
-67.00
-
May 01, 2024
herriott james
sold
-1,804
60.15
-30.00
svp, general counsel & sec

1–10 of 50

Which funds bought or sold EXAS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 17, 2024
Quantum Private Wealth, LLC
added
4.84
-1,487,710
2,660,650
0.94%
Jul 17, 2024
KRS Capital Management, LLC
sold off
-100
-213,395
-
-%
Jul 17, 2024
Yarbrough Capital, LLC
new
-
276,907
276,907
0.01%
Jul 17, 2024
KBC Group NV
unchanged
-
-587,000
924,000
-%
Jul 17, 2024
Robbins Farley
unchanged
-
-295
465
-%
Jul 17, 2024
ERn Financial, LLC
reduced
-1.26
-184,707
281,808
0.05%
Jul 17, 2024
Householder Group Estate & Retirement Specialist, LLC
sold off
-100
-78,866
-
-%
Jul 17, 2024
First PREMIER Bank
unchanged
-
-8,000
13,000
-%
Jul 17, 2024
SteelPeak Wealth, LLC
sold off
-100
-287,359
-
-%
Jul 16, 2024
Diversified Trust Co
added
3.58
-252,480
436,738
0.01%

1–10 of 45

Are Funds Buying or Selling EXAS?

Are funds buying EXAS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EXAS
No. of Funds

Unveiling Exact Sciences Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 07, 2024
jpmorgan chase & co
4.0%
7,521,686
SC 13G/A
Feb 13, 2024
vanguard group inc
9.71%
17,559,751
SC 13G/A
Feb 09, 2024
wellington management group llp
5.83%
10,536,759
SC 13G/A
Jan 29, 2024
blackrock inc.
6.1%
11,103,191
SC 13G/A
Jan 23, 2024
jpmorgan chase & co
9.5%
17,342,002
SC 13G/A
Oct 10, 2023
jpmorgan chase & co
10.3%
18,652,296
SC 13G
Feb 10, 2023
ark investment management llc
9.03%
16,040,490
SC 13G/A
Feb 09, 2023
vanguard group inc
9.71%
17,252,465
SC 13G/A
Feb 07, 2023
blackrock inc.
6.4%
11,354,134
SC 13G/A
Feb 06, 2023
wellington management group llp
5.86%
10,404,476
SC 13G/A

Recent SEC filings of Exact Sciences Corp

View All Filings
Date Filed Form Type Document
Jun 25, 2024
11-K
Employee Benefit Details
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
8-K
Current Report
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading
Jun 17, 2024
4
Insider Trading

Peers (Alternatives to Exact Sciences Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.5B
23.7B
-4.87% 13.31%
41.22
7.64
-8.94% -35.91%
38.9B
3.7B
-6.53% -14.06%
44.86
10.44
8.57% 23.94%
38.5B
6.6B
-2.21% 7.18%
30.99
5.84
-6.38% -8.07%
16.3B
9.3B
6.91% 2.58%
19.28
1.76
-3.29% 6.68%
13.1B
2.0B
5.10% 70.49%
42.03
6.69
25.57% 21.62%
12.4B
1.2B
-6.27% 109.44%
-33.99
10.28
39.26% 33.08%
11.3B
4.1B
4.10% 7.05%
25.31
2.74
0.49% -10.45%
MID-CAP
8.8B
2.5B
13.50% -51.75%
-36.53
3.46
15.21% 53.51%
3.8B
603.7M
4.01% -17.90%
-8.27
6.31
25.21% 30.68%
3.7B
929.2M
0.18% -25.49%
2.3K
3.93
28.93% 111.61%
SMALL-CAP
944.8M
275.1M
29.00% 76.56%
-5.16
3.43
-13.93% -126.97%
93.4M
31.1M
15.93% -87.44%
-1.21
3
0.95% 19.75%
18.5M
9.0M
-9.15% -62.56%
-1.26
2.06
4.46% 45.80%
403.7K
5.5M
-13.04% -72.41%
-0.03
0.07
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Exact Sciences Corp News

Latest updates
Defense World28 hours ago
Yahoo Finance29 May 202407:00 am

Exact Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-1.4%637,524,000646,885,000628,338,000622,093,000602,450,000552,995,000523,073,000521,640,000486,571,000473,812,000456,379,000434,819,000402,077,000466,339,000408,363,000268,868,000347,821,000295,575,000218,805,000199,870,000162,043,000
Cost Of Revenue-1.0%170,101,000171,865,000168,526,000156,991,000156,866,000147,152,000147,937,000144,600,000134,705,000119,058,000115,738,000113,968,000109,993,00099,765,00095,061,00077,892,00081,606,00070,416,00052,335,00051,139,00042,827,000
Gross Profit-------------------166,046,000148,307,000118,791,000
Costs and Expenses3.2%743,948,000721,126,000693,516,000699,022,000679,541,000671,877,000647,887,000681,224,000663,558,000695,262,000618,402,000606,483,000702,618,000881,318,000611,698,000359,542,000430,194,000391,655,000254,531,000233,772,000230,117,000
Operating Expenses-------------------201,706,000182,127,000186,985,000
  S&GA Expenses1.0%192,365,000190,477,000173,159,000176,490,000186,964,000210,211,000187,697,000215,922,000232,181,000284,304,000196,617,000194,827,000186,141,000166,827,000136,481,000118,862,000167,749,000119,851,00086,196,00088,190,00090,939,000
  R&D Expenses-3.8%110,608,000114,922,000111,446,000104,095,00095,419,00094,274,00090,813,000106,083,000102,248,00088,488,00075,356,000106,235,000115,567,000446,399,00031,471,00032,673,00043,509,00043,223,00034,714,00029,972,00031,785,000
EBITDA Margin-Infinity%-0.05--0.06-0.13-0.18-0.25-0.31-0.33-0.35-0.42-0.47-0.51-0.50--------
Interest Expenses-125.6%-7,943,00031,029,000-7,871,000-7,818,0004,107,00033,858,000-5,235,000-4,511,000-4,478,00032,554,000-4,680,000-4,652,000-4,616,000131,323,000-4,478,000-4,300,000-54,604,000-13,688,000-13,209,000-12,712,000-21,990,000
Income Taxes399.8%1,800,000-600,500200,0001,107,0001,700,000-2,173,000-3,100,000-1,800,000-2,000,000-4,243,000-3,858,0004,025,000-242,800,000-164,000-2,752,000-305,000-2,237,000-184,628,000683,000-443,000-470,000
Earnings Before Taxes-115.2%-108,422,000-50,376,0001,043,000-79,919,000-72,494,000-129,927,000-151,877,000-167,814,000-182,952,000-224,854,000-170,796,000-172,887,000-273,969,000-418,496,000-205,290,000-68,397,000-136,880,000-106,683,000-39,842,000-38,945,000-83,409,000
EBT Margin-16.2%-0.09-0.08-0.12-0.19-0.24-0.30-0.36-0.39-0.41-0.48-0.59-0.63---------
Net Income-121.5%-110,228,000-49,766,000794,000-81,026,000-74,151,000-127,745,000-148,761,000-166,063,000-180,937,000-220,611,000-166,938,000-176,912,000-31,164,000-418,332,000-202,538,000-68,092,000-134,643,00077,973,000-40,525,000-38,502,000-82,939,000
Net Income Margin-16.0%-0.09-0.08-0.12-0.19-0.23-0.30-0.36-0.38-0.40-0.34-0.45-0.48---------
Free Cashflow-446.4%-119,960,00034,627,000-826,00065,703,000-67,575,000-20,839,000-85,563,000-124,242,000-207,377,000-83,964,000-79,644,00015,753,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.5%6,3766,4716,4216,3566,3046,2276,3076,4376,4916,6856,6546,7246,7354,9254,3544,4684,4613,5061,7591,7821,771
  Current Assets-6.2%1,1201,1941,1481,1741,0919821,0491,1021,2151,4261,6161,6691,7752,1991,6071,5051,4845541,3201,3751,407
    Cash Equivalents-42.6%3476055956044212432352131903152743641,1041,4928077047011781,034205285
  Inventory0.8%12912713313112411811511511310595.0090.0089.0092.0080.0082.0069.0062.0054.0048.0044.00
  Net PPE0.5%702698---685--623580524502483452456463465455371335292
  Goodwill0.0%2,3672,3672,3672,3462,3462,3462,3452,3462,3352,3352,2432,24357.001,2381,2381,23830.001,203---
Liabilities-2.5%3,2443,3263,3003,2993,2473,1843,1983,2283,2323,2973,1973,1653,0862,6902,0171,9571,9231,2181,0111,016994
  Current Liabilities33.1%685515477488367413424443481517710676629633253222244236481492168
  Long Term Debt---------------1,5551,5341,51480447747025.00
    LT Debt, Current------------------1.003163120.00
    LT Debt, Non Current---------------1,5551,5341,51480447747025.00
Shareholder's Equity-0.4%3,1333,1453,1213,0573,0583,0433,1093,2093,2583,3883,4583,5593,6492,2361,7311,8871,8961,958748766777
  Retained Earnings-3.2%-3,579-3,469-3,419-3,420-3,339-3,265-3,137-2,988-2,822-2,641-2,420-2,253-2,077-2,045-1,531-1,311-1,225-1,119-1,197-1,157-1,118
  Additional Paid-In Capital1.5%6,7116,6116,5406,4766,3976,3126,2556,2056,0866,0295,8775,8115,7244,2793,8663,8203,7633,4061,9451,9201,894
Accumulated Depreciation6.9%446417-------------------
Shares Outstanding1.4%184181181181179178177176174171171171---------
Float----16,796---6,905---21,212---12,901---15,070-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-218.3%-82.3170.0024.00100-38.2252.00-40.93-60.92-173-24.57-40.7740.00-77.2311182.00-6.87-49.83-25.30-29.1517.00-74.15
  Share Based Compensation3.1%60.0059.0062.0062.0049.0046.0050.0059.0052.001135.001.0077.0042.0041.0040.0030.0048.0024.0020.0016.00
Cashflow From Investing-156.8%-171-66.77-32.9766.0083.00-58.1665.0022.0046.0078.00-49.24-793-317-30617.00-6.38-405-838857-102-41.20
Cashflow From Financing-129.9%-3.0010.000.0016.0013410.000.0063.003.00-12.200.0013.007.008804.0016.009797.001.005.00240
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EXAS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 637,524$ 602,450
Operating expenses  
Cost of sales (exclusive of amortization of acquired intangible assets)170,101156,866
Research and development110,60895,419
Sales and marketing192,365186,964
General and administrative243,117217,295
Amortization of acquired intangible assets23,31122,928
Impairment of long-lived assets4,44669
Total operating expenses743,948679,541
Other operating loss(268)0
Loss from operations(106,692)(77,091)
Other income (expense)  
Investment income, net6,213490
Interest income (expense), net(7,943)4,107
Total other income (expense)(1,730)4,597
Net loss before tax(108,422)(72,494)
Income tax expense(1,806)(1,657)
Net loss$ (110,228)$ (74,151)
Net loss per share—basic (in usd per share)$ (0.60)$ (0.42)
Weighted average common shares outstanding—basic (in shares)182,350178,574

EXAS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 347,487$ 605,378
Marketable securities304,606172,266
Accounts receivable, net240,584203,623
Inventory128,534127,475
Prepaid expenses and other current assets99,05985,627
Total current assets1,120,2701,194,369
Long-term Assets:  
Property, plant and equipment, net702,041698,354
Operating lease right-of-use assets142,017143,708
Goodwill2,367,0522,367,120
Intangible assets, net1,866,8561,890,396
Other long-term assets, net178,085177,387
Total assets6,376,3216,471,334
Current liabilities:  
Accounts payable60,49878,816
Accrued liabilities265,121341,683
Operating lease liabilities, current portion27,22529,379
Convertible Notes Payable, Current248,8100
Loans Payable, Current50,00050,000
Other current liabilities33,45514,823
Total current liabilities685,109514,701
Long-term liabilities:  
Convertible notes, net, less current portion2,066,8052,314,276
Other long-term liabilities329,384335,982
Operating lease liabilities, less current portion162,405161,070
Total liabilities3,243,7033,326,029
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at March 31, 2024 and December 31, 202300
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—183,845,188 and 181,364,180 shares at March 31, 2024 and December 31, 20231,8391,815
Additional paid-in capital6,710,6816,611,237
Accumulated other comprehensive income (loss)(499)1,428
Accumulated deficit(3,579,403)(3,469,175)
Total stockholders’ equity3,132,6183,145,305
Total liabilities and stockholders’ equity$ 6,376,321$ 6,471,334
EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
 CEO
 WEBSITEexactsciences.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES6300

Exact Sciences Corp Frequently Asked Questions


What is the ticker symbol for Exact Sciences Corp? What does EXAS stand for in stocks?

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exact Sciences Corp (EXAS)?

As of Thu Jul 18 2024, market cap of Exact Sciences Corp is 8.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers. The fair value of Exact Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exact Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXAS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exact Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

What is Exact Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 18 2024, EXAS's PE ratio (Price to Earnings) is -36.55 and Price to Sales (PS) ratio is 3.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exact Sciences Corp's stock?

In the past 10 years, Exact Sciences Corp has provided 0.111 (multiply by 100 for percentage) rate of return.